Phathom Pharmaceuticals PHAT 深 滬
等待開盤 09-18 09:30:00 美东时间
11.00
+0.020
+0.18%
華盛通- 最 高11.45
- 今 開10.96
- 成交量 176.06万股
- 最 低 10.935
- 昨 收 10.98
- 總市值 7.80亿
- 52周最高 19.50
- 市盈率 靜 --
- 換手率 2.48%
- 52周最低 2.21
- 委 比 -54.29%
- 總股本 7094.37万
- 歷史最高 64.54
- 量 比 1.92
- 振 幅 4.69%
- 歷史最低 2.21
- 每 手 1
- 風險率 3.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Theriva Biologics Has Received A Notice Of Allowance For A U.S. Patent Titled "ALKALINE PHOSPHATASE FORMULATIONS (FOR THE TREATMENT OF MICROBIOME-RELATED DISEASES)".
https://patentcenter.uspto.gov/applications/18744950/ifw/docs
09-04 03:58
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals announced that its management team will participate in two investor conferences in September: the Cantor Global Healthcare Conference on September 3-5 and the H.C. Wainwright Global Investment Conference on September 8-10. Details and webcast links are available on the company's website. Phathom focuses on developing treatments for gastrointestinal diseases, including vonoprazan for GERD and H. pylori.
08-25 11:59
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
Phathom Pharmaceuticals, Inc. clarified that Frazier Life Sciences' upcoming Schedule 13D filing, on August 20, will include administrative changes to its reporting approach but does not reflect a reduction in ownership by any Frazier fund or individual. The new filing may show a different breakdown of holdings and warrant treatment, but these changes are purely procedural and unrelated to share sales. Phathom is a biopharmaceutical company focus...
08-20 12:00
凯雷Q2继续重仓航空维修巨头StandardAero(SARO.US) 清仓文远知行(WRD.US)
全球另类资产管理巨头凯雷(CARLYLE GROUP INC)递交了截止至2025年6月30日的第二季度持仓报告(13F)。
08-13 18:47
Phathom Pharmaceuticals Sees FY2025 Sales $165.000M-$175.000M vs $159.818M Est
Phathom Pharmaceuticals (NASDAQ:PHAT) sees FY2025 sales of $165.000 million-$175.000 million vs $159.818 million analyst estimate.
08-07 21:48
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
Phathom Pharmaceuticals将举行电话会议，于2025年8月7日上午8点EDT，讨论2025年第二季度财务结果及业务更新。会议直播及更多信息可访问公司官网https://investors.phathompharma.com/news-events/events-and-presentations。录音将保存90天。公司专注于胃肠道疾病治疗产品的研发与商业化，其核心产品为vonoprazan。
07-28 12:00
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Phathom Pharmaceuticals has granted inducement awards to Anne Marie Cook upon her appointment as Chief Legal Officer and Corporate Secretary. The awards include non-qualified stock options for 210,000 shares, vesting over four years, and performance-based stock units tied to financial goals over three years, under the 2025 Inducement Plan. Phathom specializes in novel treatments for gastrointestinal diseases and markets vonoprazan-based products,...
06-23 20:15
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
Phathom Pharmaceuticals announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. With extensive experience in the pharmaceutical industry, Cook brings expertise in corporate governance, regulatory compliance, and strategic transactions. She previously held senior legal roles at Sage Therapeutics, Aegerion Pharmaceuticals, and Biogen. Cook expressed enthusiasm for contributing to Phathom's growth in gastr...
06-23 11:59
Phathom says FDA confirmed Voqueza exclusivity through May 2032
Phathom Pharmaceuticals (NASDAQ:PHAT) said that the U.S. FDA has updated its "Orange Book" to reflect that Voquezna (vonoprazan) new chemical entity exclusivity is valid through May 3, 2032. The exclu...
06-16 21:13
